Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab +/- Radiotherapy in Metastatic Melanoma
NCT01689974Phase 2Terminated
- Sponsor
- NYU Langone Health
- Start
- Jan 2013
- Primary completion
- Mar 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ipilimumab in melanoma, sponsored by NYU Langone Health. Started Jan 2013; status: terminated.
02
Drugs
ipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01689974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01689974.